Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.84M | 2.46M | 1.24M | -2.87M | -7.03M |
| Total Depreciation and Amortization | -56.00K | 34.80K | 116.90K | 242.40K | 370.40K |
| Total Amortization of Deferred Charges | 68.80K | 68.80K | 68.80K | 79.80K | 92.00K |
| Total Other Non-Cash Items | -7.82M | -7.66M | -7.51M | -3.76M | 5.20K |
| Change in Net Operating Assets | -1.99M | -1.86M | -1.72M | -912.20K | -103.60K |
| Cash from Operations | -5.96M | -6.95M | -7.81M | -7.22M | -6.67M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 3.51M | 3.51M | 3.51M | 1.77M | 16.20K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Investing | 3.51M | 3.51M | 3.51M | 1.77M | 16.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -53.00K | -89.50K | -126.00K | -141.50K | -157.00K |
| Issuance of Common Stock | 965.00K | 965.00K | 965.00K | 482.50K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 510.00K | 532.50K | 555.00K | 692.00K | 829.00K |
| Cash from Financing | 1.66M | 1.64M | 1.64M | 1.18M | 726.00K |
| Foreign Exchange rate Adjustments | 9.40K | 8.80K | 8.10K | 2.50K | -3.20K |
| Miscellaneous Cash Flow Adjustments | 1.20K | 600.00 | 100.00 | 0.00 | 0.00 |
| Net Change in Cash | -780.40K | -1.79M | -2.66M | -4.27M | -5.93M |